Transcode Therapeutics, Inc.
RNAZ· Nasdaq
RNAZTranscode Therapeutics, Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001829635-26-000003
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$6.75M | -$4.28M | -$5.19M | -$4.34M |
| EPS Diluted | -$7.17 | -$5.13 | -$680.23 | -$142.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Transcode Therapeutics, Inc. · CIK 1829635 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
